PARP Inhibitor Improves PFS in Pancreatic Cancer Subset
June 3rd 2019Maintenance therapy with olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer, according to results from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.
NCCN Expands Guidelines for Colorectal Cancer Treatment
March 25th 2019Wells A. Messersmith, MD, co-director of the developmental therapeutics program at the University of Colorado Cancer Center, said work in this area is needed to fill the knowledge gaps in metastatic CRC, which has a 5-year survival rate of just 11%.
FDA Approves Another Trastuzumab Biosimilar
March 12th 2019The FDA has granted an approval to PF-05280014 (Trazimera; trastuzumab-qyyp), a trastuzumab (Herceptin) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Oral Rivaroxaban Reduces VTE in Outpatient Treatment of Patients With Cancer
March 9th 2019Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.
Young Patients With Colorectal Cancer Are Likely to Be Misdiagnosed
February 28th 2019Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer (CRC), according to recent research presented during a webcast ahead of the 2019 AACR Annual Meeting.
Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer
January 24th 2019Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab (Keytruda), trastuzumab (Herceptin), and chemotherapy, a small clinical trial showed.
Pivotal Phase III Trial Initiated to Investigate Role of Cabozantinib in Advanced HCC
December 29th 2018A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in comparison with standard-of-care sorafenib (Nexavar) for patients with advanced hepatocellular carcinoma (HCC).
Trifluridine/Tipiracil Improves Survival in Heavily Pretreated Gastric/GEJ Cancer
November 2nd 2018Trifluridine/tipiracil (FTD/TPI; Lonsurf) reduced the risk of death in patients with heavily pretreated gastric or gastroesophageal junction (GEJ) cancer by 31% compared with placebo, according to data from the phase III TAGS trial.
Regorafenib Sustains OS Benefit in RESORCE Trial Update
September 26th 2018Regorafenib (Stivarga) maintained a prolonged overall survival (OS) benefit as second-line therapy for patients with advanced hepatocellular carcinoma (HCC) in a 2-year updated analysis of key findings from the pivotal RESORCE trial.
Published Results Confirm Regorafenib Safety, Efficacy in mCRC
September 25th 2018Safety and efficacy findings for regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (mCRC) were consistent with previous phase III results, according to findings from the phase IIIb CONSIGN trial.